Beam Therapeutics (BEAM) Jefferies London Healthcare Conference 2024 summary

Clinical data and technology milestones

• First clinical data for base editing technology in sickle cell disease shows high efficacy, with BEAM-101 achieving mid-60s fetal hemoglobin and significant reduction in sickle protein, indicating a potentially best-in-class profile.

• BEAM-101 demonstrated faster neutrophil and platelet engraftment compared to competitors, reducing hospital stays and infection risk.

• Uniform and deep gene editing achieved, with over 90% of cells edited and nearly complete elimination of sickle protein in treated patients.

• No vaso-occlusive events observed so far; efficacy and safety data continue to be monitored as the trial progresses.

• Safety profile consistent with transplant procedures; one patient death attributed to conditioning regimen, not the product.

Pipeline progress and future plans

• ESCAPE, a next-generation product, uses antibody-based conditioning to avoid chemotherapy, expanding the eligible patient population from 10% to up to 40%.

• BEAM-103 (antibody) and BEAM-104 (cell product) are moving toward IND-enabling studies, with regulatory filings expected in the back half of next year.

• Outpatient procedures may become possible with the new conditioning approach, improving patient experience and safety.

• BEAM-201 CAR-T program shows early activity, with multiple complete responses in initial patients.

Clinical trial updates and timelines

• BEACON trial for BEAM-101 in sickle cell is enrolling rapidly, with 35 of 45 patients enrolled; pivotal data for FDA filing expected in early 2026.

• ASH presentation will include updated data on seven patients for BEAM-101, deeper ESCAPE primate data, and biomarker analyses.